Curing Multiple Sclerosis: How to Know When We're There.
作者信息
Hauser Stephen L
机构信息
UCSF Weill Institute for Neurosciences and Department of Neurology, University of California, San Francisco, CA, USA.
出版信息
Ann Neurol. 2021 Oct;90(4):539-541. doi: 10.1002/ana.26155. Epub 2021 Jul 29.
Abstract
摘要
相似文献
1
Curing Multiple Sclerosis: How to Know When We're There.治愈多发性硬化症：如何知晓我们何时达成目标。
Ann Neurol. 2021 Oct;90(4):539-541. doi: 10.1002/ana.26155. Epub 2021 Jul 29.
2
The differential diagnosis of multiple sclerosis.多发性硬化的鉴别诊断
Clin Neurol Neurosurg. 2002 Jul;104(3):211-20. doi: 10.1016/s0303-8467(02)00041-0.
3
Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?利用磁共振成像定义多发性硬化症的治疗反应：多少活动量才算过多？
Arch Neurol. 2009 Jan;66(1):19-20. doi: 10.1001/archneurol.2008.529.
4
[Diagnosis of multiple sclerosis].
Rev Prat. 1999 Nov 1;49(17):1861-5.
5
Seeing injectable MS therapies differently: they are more similar than different.对注射用多发性硬化症疗法有不同看法：它们的相似之处多于不同之处。
Neurology. 2009 Jun 9;72(23):1972-3. doi: 10.1212/WNL.0b013e3181a92c82. Epub 2009 May 13.
6
Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy.多发性硬化症病理学的磁共振成像替代指标及其与中枢神经系统萎缩的关系。
J Neuroimaging. 2004 Jul;14(3 Suppl):46S-53S. doi: 10.1177/1051228404266268.
7
Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.用芬戈莫德治疗多发性硬化症：非心脏不良事件概况
Acta Neurol Belg. 2017 Dec;117(4):821-827. doi: 10.1007/s13760-017-0794-7. Epub 2017 May 20.
8
The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
Mult Scler. 2015 Sep;21(10):1240-2. doi: 10.1177/1352458515589774. Epub 2015 Aug 4.
9
The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES.
Mult Scler. 2015 Sep;21(10):1239-40. doi: 10.1177/1352458515578773. Epub 2015 Mar 31.
10
The definition of non-responder to multiple sclerosis treatment: neuroimaging markers.多发性硬化症治疗无反应者的定义：神经影像学标志物
Neurol Sci. 2008 Sep;29 Suppl 2:S222-4. doi: 10.1007/s10072-008-0943-0.
引用本文的文献
1
Epstein-Barr virus sparks brain autoimmunity in multiple sclerosis.爱泼斯坦-巴尔病毒引发多发性硬化症中的脑自身免疫。
Nature. 2022 Mar;603(7900):230-232. doi: 10.1038/d41586-022-00382-2.
本文引用的文献
1
HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis.HLA-DR15 分子共同塑造多发性硬化症中的自身反应性 T 细胞库。
Cell. 2020 Nov 25;183(5):1264-1281.e20. doi: 10.1016/j.cell.2020.09.054. Epub 2020 Oct 21.
2
Ofatumumab versus Teriflunomide in Multiple Sclerosis.奥法妥木单抗与特立氟胺治疗多发性硬化症的比较。
N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.
3
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.在两项随机临床试验的汇总分析中，复发无关进展与复发相关恶化对典型复发型多发性硬化症总体确认残疾累积的贡献。
JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568.
4
"No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?“无疾病活动证据”：这是多发性硬化症的理想治疗目标吗？
Mult Scler Relat Disord. 2020 May;40:101935. doi: 10.1016/j.msard.2020.101935. Epub 2020 Jan 9.
5
Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.自体造血干细胞移植治疗多发性硬化症后的鞘内免疫球蛋白和神经丝轻链
Mult Scler. 2020 Oct;26(11):1351-1359. doi: 10.1177/1352458519863983. Epub 2019 Jul 26.
6
Silent progression in disease activity-free relapsing multiple sclerosis.疾病活动无复发缓解型多发性硬化的静息进展。
Ann Neurol. 2019 May;85(5):653-666. doi: 10.1002/ana.25463. Epub 2019 Mar 30.
7
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.血液神经丝轻链作为 MS 疾病活动和治疗反应的生物标志物。
Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.
8
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.与多发性硬化症不同临床病程相关的发病机制。
Front Immunol. 2019 Jan 10;9:3116. doi: 10.3389/fimmu.2018.03116. eCollection 2018.
9
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.作为慢性活动性多发性硬化病变的磁共振成像标志物，病变呈缓慢扩大/演变。
Mult Scler. 2019 Dec;25(14):1915-1925. doi: 10.1177/1352458518814117. Epub 2018 Dec 19.
10
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.抗 CD19 单克隆抗体 inebilizumab（MEDI-551）治疗复发性多发性硬化症患者的安全性和耐受性：1 期随机、安慰剂对照、递增静脉和皮下剂量研究的结果。
Mult Scler. 2019 Feb;25(2):235-245. doi: 10.1177/1352458517740641. Epub 2017 Nov 16.
Zotero 插件